Evidence map›Paper›PMID 29142475›Full record

ArticleWorld journal of gastroenterology2017

Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.

Beilei Cai, Michael S Broder, Eunice Chang, Tingjian Yan, David C Metz

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. An unusual case of chronic diarrhea: a case report.Internal and emergency medicine · 2022
    Article
  4. Sex differences in carcinoid syndrome: A gap to be closed.Reviews in endocrine & metabolic disorders · 2022
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Beilei CaiNovartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, United States. beilei.cai@novartis.com.
Michael S BroderPartnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Beverly Hills, CA 90212, United States.
Eunice ChangPartnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Beverly Hills, CA 90212, United States.
Tingjian YanPartnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Beverly Hills, CA 90212, United States.
David C MetzDivision of Gastroenterology, University of Pennsylvania Health System, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, Philadelphia, PA 19104, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo discover unknown factors associated with carcinoid syndrome (CS) with the goal of earlier diagnosis of CS.

methodsIn this retrospective case-control study using United States administrative claims, patients (≥ 18 years) newly-diagnosed with gastrointestinal neuroendocrine tumors (GI NETs) without CS (controls) were exactly matched to patients with CS (cases) based on NET diagnosis date at a 3-to-1 ratio. Study index date was first CS diagnosis (controls: same distance from NET diagnosis as cases). The most observed conditions, excluding CS-associated symptoms/diagnoses, during the year before index date were assessed. Forward-stepwise logistic regression models were used to derive predictors, and were validation within another claims database.

resultsIn the development database, 1004 patients with GI NETs were identified; 251 (25%) had CS and 753 (75%) were controls. In the validation database, 724 patients with GI NETs were identified; 181 (25%) had CS and 543 (75%) were controls. A total of 33 common diagnoses (excluding conditions already known to be associated with CS) in the development database were entered in forward step-wise logistic regression models. In the final, validated logistic regression model, three factors prior to CS diagnosis were found consistently associated with higher risks for CS, including liver disorder [odds ratio (95%CI): 3.38 (2.07-5.51)], enlargement of lymph nodes [2.13 (1.10-4.11)], and abdominal mass [3.79 (1.87-7.69)].

conclusionGI NET patients with CS were 2-4 times as likely to have preexisting diagnoses (

Indexed as

AdultAgedCase-Control StudiesFemaleGastrointestinal NeoplasmsHumansIncidenceLogistic ModelsMaleMalignant Carcinoid SyndromeMiddle AgedNeuroendocrine TumorsRetrospective StudiesRisk FactorsUnited StatesYoung AdultCarcinoid syndromeData miningGastrointestinal neuroendocrine tumorsPredictive factors

Identifiers

PMID29142475
PMCPMC5677203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.